JP2021522839A - 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット - Google Patents

増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット Download PDF

Info

Publication number
JP2021522839A
JP2021522839A JP2020564137A JP2020564137A JP2021522839A JP 2021522839 A JP2021522839 A JP 2021522839A JP 2020564137 A JP2020564137 A JP 2020564137A JP 2020564137 A JP2020564137 A JP 2020564137A JP 2021522839 A JP2021522839 A JP 2021522839A
Authority
JP
Japan
Prior art keywords
cells
composition
cell
subset
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522839A5 (enExample
Inventor
ギー ディピエッロ
ギー ディピエッロ
サントス ゲイリー ドス
サントス ゲイリー ドス
Original Assignee
インダプタ セラピューティクス インコーポレイテッド
インダプタ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インダプタ セラピューティクス インコーポレイテッド, インダプタ セラピューティクス インコーポレイテッド filed Critical インダプタ セラピューティクス インコーポレイテッド
Publication of JP2021522839A publication Critical patent/JP2021522839A/ja
Publication of JP2021522839A5 publication Critical patent/JP2021522839A5/ja
Priority to JP2024067406A priority Critical patent/JP2024096956A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020564137A 2018-05-14 2019-05-14 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット Pending JP2021522839A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024067406A JP2024096956A (ja) 2018-05-14 2024-04-18 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671358P 2018-05-14 2018-05-14
US62/671,358 2018-05-14
PCT/US2019/032318 WO2019222293A1 (en) 2018-05-14 2019-05-14 Subsets of human natural killer cells with enhanced antibody-directed immune responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024067406A Division JP2024096956A (ja) 2018-05-14 2024-04-18 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット

Publications (2)

Publication Number Publication Date
JP2021522839A true JP2021522839A (ja) 2021-09-02
JP2021522839A5 JP2021522839A5 (enExample) 2022-05-19

Family

ID=68541145

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564137A Pending JP2021522839A (ja) 2018-05-14 2019-05-14 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット
JP2024067406A Pending JP2024096956A (ja) 2018-05-14 2024-04-18 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024067406A Pending JP2024096956A (ja) 2018-05-14 2024-04-18 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット

Country Status (10)

Country Link
US (1) US20210187025A1 (enExample)
EP (2) EP4474391A3 (enExample)
JP (2) JP2021522839A (enExample)
CN (1) CN112839666A (enExample)
AU (1) AU2019271146A1 (enExample)
CA (1) CA3099806A1 (enExample)
DK (1) DK3793573T3 (enExample)
ES (1) ES2993360T3 (enExample)
PT (1) PT3793573T (enExample)
WO (1) WO2019222293A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10066207B2 (en) 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
AU2018219895C1 (en) 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
EP3884041A2 (en) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
KR20230088306A (ko) * 2020-04-22 2023-06-19 인답타 세라뷰틱스 인코포레이티드 자연 살해(ｎｋ) 세포 조성물 및 이를 생성하는 방법
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
KR20240024048A (ko) * 2021-04-08 2024-02-23 아티바 바이오테라퓨틱스, 인크. Nk 세포와 her2 표적 항체를 이용한 암 치료 방법
AU2022254978A1 (en) 2021-04-08 2023-11-16 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and a cd20 targeted antibody
KR20240024047A (ko) 2021-04-08 2024-02-23 아티바 바이오테라퓨틱스, 인크. Nk 세포와 cd38 표적 항체를 이용한 암 치료 방법
CN117529327A (zh) * 2021-04-08 2024-02-06 埃迪瓦生物治疗公司 用nk细胞和靶向cd20的抗体治疗肿瘤
CN117715647A (zh) * 2021-04-08 2024-03-15 埃迪瓦生物治疗公司 用nk细胞和cd38靶向抗体治疗癌症
US20240366664A1 (en) * 2021-04-08 2024-11-07 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and an egfr targeted antibody
US20240197783A1 (en) * 2021-04-21 2024-06-20 Indapta Therapeutics, Inc. Methods of treatment and dosing of natural killer cell compositions
CN115521913B (zh) * 2022-02-22 2023-07-25 北京景达生物科技有限公司 NK细胞与CD20、CD38、Her2抗体联合应用
CN116679065B (zh) * 2023-07-31 2023-11-14 北京大学人民医院 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500832A (ja) * 2004-06-01 2008-01-17 サントル・オスピタリエ・レジオナル・エ・ユニヴェルシタイル・ドゥ・トゥール Ｆｃｇｒ３ａゲボタイプ（ｇｅｂｏｔｙｐｅ）および非枯渇性抗体に対する処置応答を評価するための方法
WO2009041113A1 (ja) * 2007-09-28 2009-04-02 Olympus Corporation Fc受容体遺伝子導入ＮＫ細胞、その作製方法、及びこれを用いた抗体依存性細胞障害のアッセイ方法
US20130295044A1 (en) * 2012-04-18 2013-11-07 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
WO2016077734A2 (en) * 2014-11-14 2016-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors
JP2020507349A (ja) * 2017-02-09 2020-03-12 インダプタ セラピューティクス インコーポレイテッド 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6016891A (en) 1998-08-10 2000-01-25 Sava; John G. Tree stand harness system
ES2678094T3 (es) * 2004-07-10 2018-08-08 Fox Chase Cancer Center Líneas de células asesinas naturales genéticamente modificadas
WO2012061814A1 (en) 2010-11-05 2012-05-10 Transgenomic, Inc. Pcr primers and methods for rapid and specific genotyping

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500832A (ja) * 2004-06-01 2008-01-17 サントル・オスピタリエ・レジオナル・エ・ユニヴェルシタイル・ドゥ・トゥール Ｆｃｇｒ３ａゲボタイプ（ｇｅｂｏｔｙｐｅ）および非枯渇性抗体に対する処置応答を評価するための方法
WO2009041113A1 (ja) * 2007-09-28 2009-04-02 Olympus Corporation Fc受容体遺伝子導入ＮＫ細胞、その作製方法、及びこれを用いた抗体依存性細胞障害のアッセイ方法
US20130295044A1 (en) * 2012-04-18 2013-11-07 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
WO2016077734A2 (en) * 2014-11-14 2016-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors
JP2020507349A (ja) * 2017-02-09 2020-03-12 インダプタ セラピューティクス インコーポレイテッド 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法

Also Published As

Publication number Publication date
CN112839666A (zh) 2021-05-25
EP3793573A1 (en) 2021-03-24
WO2019222293A1 (en) 2019-11-21
EP3793573B1 (en) 2024-10-23
EP3793573A4 (en) 2022-01-26
US20210187025A1 (en) 2021-06-24
CA3099806A1 (en) 2019-11-21
EP4474391A3 (en) 2025-02-26
AU2019271146A1 (en) 2020-12-10
PT3793573T (pt) 2024-11-05
EP4474391A2 (en) 2024-12-11
DK3793573T3 (da) 2024-11-25
JP2024096956A (ja) 2024-07-17
ES2993360T3 (en) 2024-12-27

Similar Documents

Publication Publication Date Title
EP3793573B1 (en) Subsets of human natural killer cells with enhanced antibody-directed immune responses
US20260043006A1 (en) Methods for expansion of natural killer (nk) cell subset and related compositions and methods
JP2026048701A (ja) キメラ抗原受容体発現細胞を作製する方法
US12564739B2 (en) Engineered natural killer (NK) cells and compositions and methods thereof
JP2021534783A (ja) キメラ抗原受容体発現細胞を作製する方法
US11141471B2 (en) Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells
CN113766919B (zh) 制造抗bcma car t细胞
US20230190801A1 (en) Natural killer (nk) cell compositions and methods for generating same
US20240197783A1 (en) Methods of treatment and dosing of natural killer cell compositions

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230531

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231218